Indeed, downregulation or loss of CADM1 expression is frequently observed in various cancers, such as NSCLC, HCC, cervix, prostate and pancreas cancer [30–35], especially in those with LNM and DM [36]. Here, CADM1 is linked to hepatocellular carcinoma.